International Journal of Clinical Obstetrics and Gynaecology

Background: Pregnancy rate decreases as age advances because of poor ovarian reserve. For women with diminished ovarian reserve (DOR) Sr. AMH <1.2, the experimental trial of intra-ovarian injection of human umbilical cord mesenchymal stem cells combined with autologous platelet-rich plasma has been done. The purpose of this trial is to assess the impact of this intervention on poor AMH, AFC count, embryo quality, clinical pregnancy, and live birth outcomes.

Materials and Methods: The study includes 82 infertile women who were between the ages of 25 and over 40, who had their first IVF cycle. Both ovaries received intra-ovarian injections of autologous platelet-rich plasma and human umbilical cord mesenchymal stem cells. Data on the improvement of AMH, the number and the count of antral follicles were gathered after three months. Next, we contrasted the data obtained prior and following of the treatment.

Results: Women treated with HUC-MSCs with PRP had a substantial rise in AFC count at the 2-month follow-up. Moreover, the AMH value was moderately increased and observed few antral follicles count after the therapy. Total 35 patients achieved pregnancy whereas 16 patients delivered single baby and 2 patients delivered twin babies.

Conclusion: We established the role of intraovarian injection of autologous platelet-rich plasma and human umbilical cord mesenchymal stem cells helped patients with low ovarian reserve to conceive. Therefore, in order to treat the condition of reduced ovarian reserve and premature ovarian failure, ovarian rejuvenation can be an option.